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Abstract
Objectives
Health-related quality of life (HRQoL) is considered a very important outcome indicator in
patients with Parkinson’s disease (PD). A broad list of motor and non-motor features have
been shown to affect HRQoL in PD, however, there is a dearth of information about the
complexity of interrelationships between determinants of HRQoL in different PD pheno-
types. We aimed to find independent determinates and the best structural model for
HRQoL, also to investigate the heterogeneity in HRQoL between PD patients with different
phenotypes regarding onset-age, progression rate and dominant symptom.
Methods
A broad spectrum of demographic, motor and non-motor characteristics were collected in
157 idiopathic PD patients, namely comorbidity profile, nutritional status, UPDRS (total
items), psychiatric symptoms (depression, anxiety), fatigue and psychosocial functioning
through physical examination, validated questionnaires and scales. Structural equation
model (SEM) and multivariate regressions were applied to find determinants of Parkinson’s
disease summary index (PDSI) and different domains of HRQoL (PDQ-39).
Results
Female sex, anxiety, depression and UPDRS-part II scores were the significant indepen-
dent determinants of PDSI. A structural model consisting of global motor, global non-motor
and co-morbidity indicator as three main components was able to predict 89% of the
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variance in HRQoL. In older-onset and slow-progression phenotypes, the motor domain
showed smaller contribution on HRQoL and the majority of its effects were mediated
through non-motor features. Comorbidity component was a significant determinant of
HRQoL only among older-onset and non-tremor-dominant PD patients. Fatigue was not a
significant indicator of non-motor component to affect HRQoL in rapid-progression PD.
Conclusions
Our findings showed outstanding heterogeneities in the pattern and determinants of
HRQoL among PD phenotypes. These factors should be considered during the assess-
ments and developing personalized interventions to improve HRQOL in PD patients with
different phenotypes or prominent feature.
Introduction
Both the chronic nature and the wide spectrum of Parkinson’s disease (PD) manifestations
affect several aspects of patients’ daily life. Thus, health-related quality of life (HRQoL) has
been considered as an important outcome indicator for management, care and progression of
PD[1]. Quite recently, many studies have investigated the impact of different variables on
HRQoL in PD patients including disease severity, motor symptoms, non-motor symptoms,
nutritional status, demographic and socioeconomic characteristics[1,2,3,4,5,6,7,8,9]. Yet, a few
of them have included the broad range of parkinsonian features all together and compare their
independent role and strength of their affect on HRQoL. On the other hand, patients with PD
show significant heterogeneity in their motor and non-motor features[10], which is a great
obstacle in generalizability of the pattern of HRQoL for PD patients with different phenotypes.
While the National Institutes of Health has recently delineated subtype-identification as one of
the top priorities in the field of PD clinical research[11], there is a dearth of information about
determinants of QoL in different PD subtypes.
Having evaluated a broad spectrum of baseline, sociodemographic, nutritional, motor and
non-motor features of PD, we intended to apply advanced statistical methods namely multivar-
iate regressions and structural equation modeling (SEM) to: 1) investigate the factors that affect
HRQoL in PD patients, 2) compare their independence and strength of their effects on
HRQoL, 3) model HRQoL with the best hypothesized structural model and 4) explore the
structural heterogeneity in the optimum model for HRQoL within different PD phenotypes.
Materials and Methods
Study Setting & Subjects
This study was conducted on 157 patients with idiopathic Parkinson’s disease (IPD), which
were consecutively recruited from an outpatient referral movement disorder clinic in Tehran,
Iran. The ethics committee of the neurology department at Firoozgar Clinical Research Devel-
opment Center (FCRDC) approved the study protocol and informed consent was verbally
obtained from all participants. Since this project was designed as an observational study and no
intervention was applied for research purposes, the verbal form of consent was approved by
the aforementioned ethics committee according to their instructions. Following inclusion crite-
ria were applied to enroll the patients: diagnosis of IPD based on the UK brain bank criteria
[12], current age35 years, and to be cognitively eligible to validly answer the questionnaires.
Quality of Life in Parkinson's Disease
PLOS ONE | DOI:10.1371/journal.pone.0137081 September 3, 2015 2 / 17
Cognitive status was judged through interview by the neurologist and patients with severe
dementia who gave invalid answers were excluded.
Three phenotyping approaches were used to divide study participants into different sub-
groups as follows:
a. Onset-age: younger-onset (n = 50, diagnostic age50 yr) versus older-onset (n = 106,
diagnostic age>50 yr)
b. Progression: slow (n = 95) versus rapid (n = 40) based on the clustering solution recom-
mended by Gasparoli et al using Unified Parkinson's Disease Rating Scale (UPDRS)-Part II,
UPDRS-Part III, dyskinesia and motor fluctuations as the clustering characteristics [13]
c. Dominant symptom: tremor (n = 76) versus non-tremor (n = 75) based on the median
value of the tremor motor score (cut-off value = 13.3)
Assessments
Data collection was performed through interviews with eligible patients by a trained group of
medical interns to fill validated questionnaires and scales. One neurologist specialized in move-
ment disorders examined all patients for clinical assessment and diagnosis. Demographic and
baseline data were collected by means of a checklist. Assessment of clinical characteristics and
HRQoL were performed during the “On” status consisting of:
Motor Severity
a. Unified Parkinson's Disease Rating Scale (UPDRS) subscales I—IV
b. Hoehn and Yahr (H & Y) staging
c. Schwab and England activities of daily living (ADL)
d. Dyskinesia score: sum of UPDRS-Part IV items 32–34
e. Fluctuation score: sum of UPDRS-Part IV items 36–39
Motor Subtypes
a. Postural-instability-gait-difficulty (PIGD) score: sum of UPDRS-Part III items concerning
rise, gait, and postural instability
b. FOSS score: sum of UPDRS-Part II items on freezing, speech and swallowing
c. Predominance of core manifestations: proportion of UPDRS-Part III ‘‘on”motor scores
accounted for tremor (items 20–21), rigidity (item 22), bradykinesia (items 23–26 and
31), and gait (items 27–30) in percentage
d. Asymmetry index: absolute differences in UPDRS between sides divided by the total
UPDRS III (0 = perfect symmetry, 1 = absolute asymmetry)
e. Axial/limb ratio: sum of UPDRS-Part III items 18, 19, 22 and 27–30 divided by sum of
UPDRS-Part III items 20–26
f. Presence of falls and freezing
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Non-Motor Manifestations
a. Depression: using the Persian-translated and validated version of the Hospital Anxiety
and Depression Score (HADS)[14] consisting of 7 items for depression scored between 0
to 21 where higher scores show more severe depressive symptoms
b. Anxiety: assessed by HADS similar to depression
c. Hallucinations/Illusions: evaluated using UPDRS-Part I, item 2
d. Apathy: evaluated using UPDRS-Part I, item 4
e. Fatigue: by means of the Persian-translated and validated version of the Fatigue Severity
Scale (FSS) [15], which includes 9 questions with a total score ranging from 0 to 7 (higher
scores correspond more severe fatigue)
f. Nutritional status: using the Persian-translated and validated version of the Mini Nutri-
tional Assessment (MNA)[16] including anthropometric measurements of body mass
index (BMI), body mass index (BMI), arm and calf circumferences totally scoring between
0 to 30 where higher scores demonstrate better status
g. Psychosocial functioning: evaluated by the Persian-translated and validated version of the
scales for outcomes in Parkinson's disease-psychosocial questionnaire (SCOPA-PS)[17],
which consists of 11 items and a summary index that is scored between 0 to 100% (higher
score corresponds a worse condition)
Health-Related Quality of Life (HRQoL)
Validated Persian version of the 39-item PD questionnaire (PDQ-39)[18] was applied to assess
HRQoL. Other than domain-specific scores, PD summary index (PDSI) was calculated as the
mean score of all domains. PDSI varies between 0 to 100% and a higher score indicates poorer
HRQoL in PD patients.
Detailed participant-level information on all variables and measurements is presented in
S1 Text.
Statistical Analysis
For description of numerical variables, mean and standard deviation (SD) were used except for
discrete values where median and interquartile range (IQR) was reported. We applied univari-
ate linear regression to calculate beta correlation coefficients and their 95% confidence interval
(CI) between baseline and clinical characteristics with the numeric PDSI score. Prior to per-
form further analyses and in order to avoid case-wise deletion and decreased statistical power,
95 single missing values (0.25% of the whole datasheet) were imputed using multiple regres-
sions. Two-step cluster analysis was used to implement the clustering solution recommended
by Gasparoli et al[13] to divide PD patients into slow-progression versus rapid-progression
phenotypes. Multivariate linear regression was performed using the list of significant univariate
demographic variables for adjustment, and the best representative variables from motor sever-
ity, motor subtypes and non-motor assessments. We avoided including correlated indicators of
one single entity. Tolerance index representing the proportion of variance for each indepen-
dent variable that are not explained by other independent variables in the model, were calcu-
lated and were considered acceptable if>0.4. Conventionally, the variance inflation factor
(VIF) (1/tolerance) was also reported and aimed to be<2.5 to avoid collinearity in the models.
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If the collinearity occurred, then the variable with higher tolerance and larger standardized
coefficient was kept and the other collinear variable was deleted from the regression model.
Furthermore, a structural equation model (SEM) was applied to construct a hypothetical
model with three latent variables representing global motor, non-motor and HRQoL compo-
nents. After structural modifications, standardized regression weight (SRW) for each included
component was reported. Fitness of each SEM was assessed using the absolute fit indices con-
sisting of Normed Fit Index (NFI), Comparative Fit Index (CFI), Tucker-Lewis Index (TLI)
and Root Mean Square Error of Approximation (RMSEA). An NFI, CFI and TLI value between
0.06 and 0.08 and RMSEA<0.08 indicate an acceptable model fit[19].
Results
Baseline Characteristics
Study participants consisted of 157 IPD patients, 108 (68.8%) males and 49 (31.2%) females,
with the mean age of 61.4 (SD = 11.2) yr at the time of enrollment and average PD duration of
6.8 (SD = 5.2) yr. The mean of total UPDRS score was 32.2 (SD = 18.1) and the median Hoehn
and Yahr stage was 2 (IQR = 1.5). Other demographic and clinical characteristics including
motor severity, motor subtype, non-motor assessments and HRQoL scores are listed in
Table 1. The worst dimension-specific scores of the PDQ-39 questionnaire were observed in
the “emotional well-being” [28.4 (SD = 23.6)] and “mobility” [28.2 (SD = 26.4)] domains and
the average value of the PDSI was 21.2 (SD = 15.4).
Univariate Associations
Table 2 shows the univariate linear correlations between baseline characteristics, motor severity
and subtypes, and non-motor scales with PDSI as a single indicator of HRQoL in the whole
study participants. Among demographic characteristics, female sex [unadjusted coeffi-
cient = 10.40 (95%CI: 5.41–15.38)], lower education [unadjusted coefficient = -5.03 (95%CI:
-7.26 – -2.80)], higher number of comorbidities [unadjusted coefficient = 3.07 (95%CI: 0.59–
5.54)] and higher weight-adjusted daily levodopa dose [unadjusted coefficient = 0.48 (95%CI:
0.16–0.80)] were all related to higher PDSI. Several motor and non-motor variables including
all parts of UPDRS, psychiatric symptoms, fatigue and psychosocial functioning were signifi-
cantly correlated with the PDSI (Table 2).
Multivariate Regression
The results from multivariate linear regression models to find the independent predictors of
HRQoL evaluated by the PDSI and within different dimensions of the PDQ-39 are summarized
in Table 3. Using sex, level of education, comorbidity score and PD duration as the baseline
covariates, anxiety [adjusted coefficient = 0.51 (95%CI: 0.15–0.87)], depression [adjusted coef-
ficient = 1.11 (95%CI: 0.63–1.59)] and UPDRS-part II (ADL) [adjusted coefficient = 0.90 (95%
CI: 0.60–1.20)] scores were the significant independent determinants of PDSI. In dimension-
specific analysis, female sex, higher depression score and more impaired ADL (UPDRS-Part II)
were shown to be the statistically significant predictors of worse HRQoL in “mobility” and
“social support” domains (all adjusted coefficients >0 and p<0.05). “Emotional well-being”
was significantly worse in IPD patients who were female [adjusted coefficient = 7.18 (95%CI:
1.02–13.34)], scored higher for anxiety [adjusted coefficient = 1.65 (95%CI: 0.98–2.31)] and
depression [adjusted coefficient = 1.99 (95%CI: 1.11–2.88)] and had less severe motor signs
(UPDRS-Part III) [adjusted coefficient = -0.53 (95%CI: -0.93 – -0.12)]. Furthermore, higher
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Table 1. Baseline and clinical characteristics of the Parkinson’s disease patients (n = 157).
Characteristics Value
Demography and General Information
Age-year (mean ± SD)
Current 61.4 ± 11.2
At disease onset 54.7 ± 11.9
Gender NO (%)
Female 49 (31.2)
Male 108 (68.8)
Level of Education NO (%)
Illiterate 17 (11.0)
Primary and/ or secondary 37 (23.9)
High school/diploma 43 (27.7)
College and/ or university 58 (37.4)
Comorbidities NO (%)
Hypertension 28 (18.1)
Ischemic heart disease 24 (15.7)
Osteoarthritis 19 (12.4)
Diabetes 20 (13.1)
Stroke/Transient ischemic attack 1 (0.7)
Chronic obstructive pulmonary disease 1 (0.7)
Total score (mean ± SD) 0.6 ± 1.0
Duration of Parkinson’s Disease-year (mean ± SD) 6.8 ± 5.2
Levodopa Dose-mg (mean ± SD)
Cumulative daily dose 864.7 ± 447.8
Weight-adjusted daily dose 12.6 ± 7.2
Motor Severity
UPDRS Score (mean ± SD)
Part II- ADL 11.7 ± 7.4
Part III- Motor 15.5 ± 9.2
Part IV- Complications 3.4 ± 2.8
Dyskinesia 0.9 ± 1.7
Fluctuations 1.7 ± 1.3
Total score 32.2 ± 18.1
Hoehn and Yahr Stage median (IQR) 2 (1.5)
Schwab and England Activities of Daily Living Score-(%) (mean ± SD) 80.5 ± 18.0
Motor Impairment Score A1 (mean ± SD) 11.5 ± 6.3
Motor Impairment Score B2 (mean ± SD) 4.0 ± 3.6
Motor Subtypes
Tremor-% of UPDRS-Part III (mean ± SD) 14.9 ± 13.7
Rigidity-% of UPDRS-Part III (mean ± SD) 10.2 ± 7.2
Bradykinesia-% of UPDRS-Part III (mean ± SD) 41.3 ± 17.3
Gait-% of UPDRS-Part III (mean ± SD) 17.7 ± 12.2
Freezing N (%) 54 (34.4)
Falls N (%) 62 (39.5)
Axial/Limb Ratio (mean ± SD) 0.9 ± 0.7
Asymmetry Index (mean ± SD) 0.2 ±0.2
PIGD Score (mean ± SD) 2.3 ± 2.4
FOSS Score (mean ± SD) 1.7 ± 1.7
(Continued)
Quality of Life in Parkinson's Disease
PLOS ONE | DOI:10.1371/journal.pone.0137081 September 3, 2015 6 / 17
number of comorbidities [adjusted coefficient = 2.63 (95%CI: 0.02–5.24)] accompanied with a
worse “cognition” dimension of the HRQoL in IPD patients.
Structural Equation Modeling
Fig 1 illustrates the hypothetical structural model for the factors affecting HRQoL in IPD
patients. With RMSEA = 0.08, NFI = 0.74, CFI = 0.84 and TLI = 0.82, the model could accept-
ably explain 89% of the variance of HRQoL. Three direct correlations (cognition and hallucina-
tion in the non-motor section, anxiety on “emotional well-being” dimension of HRQoL, “social
support” and “communication” dimensions of HRQoL) were added in order to improve the
model. Among the entire study samples, non-motor latent domain had a larger direct effect on
HRQoL compared to that of the motor (SRW = 0.69 vs. 0.32), while the motor domain showed
Table 1. (Continued)
Characteristics Value
Non-Motor Assessments
UPDRS Score (mean ± SD)
Part I- Mental 2.1 ± 2.4
Cognitive Impairment N (%) 47 (29.9)
Hallucination N (%) 19 (12.1)
Apathy N (%) 58 (37.2)
Sleep Disturbances N (%) 58 (36.9)
Orthostasis N (%) 28 (17.8)
Anxiety Score (HADS) (mean ± SD) 6.8 ± 5.1
Depression Score (HADS) (mean ± SD) 5.1 ± 4.4
Fatigue Score (FSS) (mean ± SD) 4.5 ± 1.9
Nutritional Status (MNA) (mean ± SD)
Screening score 12.7 ± 2.0
Assessment score 12.6 ± 1.9
Total score 25.2 ± 3.3
Psychosocial Functioning Score (SCOPA-PS)-(%) (mean ± SD) 25.9 ± 22.3
Health-Related Quality of Life (HRQoL)
Quality of Life (PDQ-39) (mean ± SD)
Dimension I-Mobility 28.2 ± 26.4
Dimension II-Activity of daily living (ADL) 26.4 ± 25.6
Dimension III-Emotional well-being 28.4 ± 23.6
Dimension IV-Stigma 21.9 ± 25.2
Dimension V-Social support 11.5 ± 20.3
Dimension VI-Cognitions 17.9 ± 20.1
Dimension VII-Communication 15.1 ± 19.5
Dimension VIII-Bodily Discomfort 22.1 ± 23.0
Parkinson’s disease summary index (PDSI) (mean ± SD) 21.2 ± 15.4
SD: standard deviation; IQR: interquartile range; PIGD: postural-instability-gait-difficulty; FOSS: freezing-
speech-swallowing
1 Score A is the sum of UPDRS-Part III items concerning facial expression, tremor, rigidity, and
Bradykinesia which are considered relatively L-dopa responsive
2 Score B is the sum of UPDRS-Part III items concerning speech and axial impairment (arising from chair,
posture, postural stability, gait) which are considered relatively L-dopa non-responsive.
doi:10.1371/journal.pone.0137081.t001
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Table 2. Univariate linear correlations between the baseline and clinical characteristics with Parkin-
son’s disease summary index (PDSI) of the health-related quality of life (HRQoL) (n = 157).
Characteristics Univariate Coefficient β (95% confidence
interval)
p-value
Demography
Onset Age -0.05 (-0.25–0.16) 0.655
Female Sex 10.40 (5.41–15.38) <0.001*
Level of Education -5.03 (-7.26 – -2.80) <0.001*
Comorbidity Score1 3.07 (0.59–5.54) 0.016*
Duration of Parkinson’s Disease 0.56 (0.10–1.02) 0.017*
Levodopa Treatment
Cumulative daily dose 0.01 (0–0.01) 0.064
Weight-adjusted daily dose 0.48 (0.16–0.80) 0.004*
Motor Severity
UPDRS Score
Part II- ADL 1.34 (1.08–1.59) <0.001*
Part III- Motor 0.71 (0.47–0.95) <0.001*
Part IV
Dyskinesia score 1.18 (-0.23–2.59) 0.100
Fluctuations score 0.09 (-1.83–2.01) 0.926
Total score 0.53 (0.41–0.64) <0.001*
Hoehn and Yahr Stage 6.16 (3.61–8.70) <0.001*
Schwab and England Activities of Daily
Living Score
-0.48 (-0.59 – -0.37) <0.001*
Motor Impairment Score A2 0.93 (0.57–1.29) <0.001*
Motor Impairment Score B3 1.71 (1.07–2.34) <0.001*
Motor Subtypes
Tremor-% of UPDRS-Part III -0.26 (-0.44 – -0.08) 0.006*
Rigidity-% of UPDRS-Part III -0.42 (-0.77 – -0.08) 0.017*
Bradykinesia-% of UPDRS-Part III 0.12 (-0.03–0.26) 0.108
Gait-% of UPDRS-Part III 0.19 (-0.02–0.39) 0.077
Freezing 13.33 (8.67–18.00) <0.001*
Falls 12.15 (7.56–16.74) <0.001*
Axial/Limb Ratio 0.03 (-3.37–3.43) 0.984
Asymmetry Index -18.91 (-29.10 – -8.72) <0.001*
PIGD Score 2.34 (1.38–3.31) <0.001*
FOSS Score 4.65 (3.43–5.88) <0.001*
Non-Motor Assessments
UPDRS Score
Part I- Mental 3.63 (2.74–4.51) <0.001*
Cognitive Impairment 7.98 (2.82–13.14) 0.003*
Hallucination 16.66 (9.68–23.63) <0.001*
Apathy 12.75 (8.12–17.39) <0.001*
Sleep Disturbances 8.93 (4.09–13.77) <0.001*
Orthostasis 3.52 (-2.82–9.85) 0.274
Anxiety Score (HADS) 1.75 (1.36–2.14) <0.001*
Depression Score (HADS) 2.47 (2.07–2.87) <0.001*
Fatigue Score (FSS) 3.63 (2.47–4.79) <0.001*
Nutritional Status (MNA)
Screening score -2.37 (-3.45 – -1.29) <0.001*
(Continued)
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an indirect effect mediated through the non-motor section as large as 0.49 resulting in the
total effect of 0.81. UPDRS-Part II (ADL) (SRW = 0.94), UPDRS-Part III (motor signs)
(SRW = 0.70) and falling (SRW = 0.70) were the strongest indicators of the motor latent
variable. Psychosocial functioning (SRW = 0.84), depression (SRW = 0.82) and anxiety
(SRW = 0.63) were the most determinant factors for the non-motor latent domain to affect
HRQoL.
The same hypothetical SEM was rerun in subgroups of PD with different phenotypes. As
it is shown in Table 4, motor domain showed larger direct impact on HRQoL compared to
non-motor section in younger-onset (SRW = 0.61, p<0.001)and rapid-progression PD
(SRW = 0.57, p<0.001), whereas in other phenotypes non-motor domain had larger direct
effect (all p<0.05). Among patients with slow-progression PD, non-motor domain showed the
largest direct effect (SRW = 0.95, p = 0.005) on HRQoL and all of the effects of motor domain
was mediated through non-motor section. Even though small, comorbid conditions showed
significant effect on HRQoL among those with>50 years of age at the time of diagnosis
(SRW = 0.14, p = 0.007) and non-tremor-dominant PD (SRW = 0.13, p = 0.037). In younger-
onset patients, sleep disorder was not an important indicator of the non-motor latent variable,
while depression was its strongest driver (SRW = 0.91, p = 0.004).Opposite to slow-progression
phenotype, fatigue was shown to be a non-significant indicator for non-motor domain among
those categorized as rapid-progression. In contrast to all other phenotypes, both dyskinesia
(SRW = 0.42, p = 0.012) and fluctuations (SRW = 0.33, p = 0.043) remained significant indica-
tors for motor domain in the younger-onset patients. “Stigma” was found to be an important
indicator for HRQoL only in older-onset (SRW = 0.39, p<0.001), slow-progression (SRW =
0.33, p = 0.003) and non-tremor-dominant (SRW = 0.49, p<0.001) subgroups. “Cognition”
had the highest SRW as an indicator of HRQoL among the older-onset patients (0.72), whereas
“mobility” showed the largest SRW in younger-onset phenotype (0.90).
Discussion
Capitalizing upon comprehensively evaluated variables and in addition to the broad list of
motor and non-motor features, comorbidity profile and nutritional status were also included
in our analysis, which have been mainly ignored in many previous studies as determinant fac-
tors of HRQoL in PD. HRQoL was found to be poorer in females, those with lower level of edu-
cation, higher number of comorbid conditions and longer duration of disease. Interestingly,
Table 2. (Continued)
Characteristics Univariate Coefficient β (95% confidence
interval)
p-value
Assessment score -4.39 (-5.40 – -3.39) <0.001*
Total score -2.41 (-3.05 – -1.77) <0.001*
Psychosocial Functioning Score
(SCOPA-PS)
0.55 (0.48–0.62) <0.001*
PIGD: postural-instability-gait-difficulty; FOSS: freezing-speech-swallowing
* Statistical significant correlation (two-tailed p-value<0.05)
1 Total number of comorbidities
2 Score A is the sum of UPDRS-Part III items concerning facial expression, tremor, rigidity, and
Bradykinesia which are considered relatively L-dopa responsive
3 Score B is the sum of UPDRS-Part III items concerning speech and axial impairment (arising from chair,
posture, postural stability, gait) which are considered relatively L-dopa non-responsive.
doi:10.1371/journal.pone.0137081.t002
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Table 3. Multivariate linear regressionmodels to find the baseline and clinical predictors of the Parkinson’s disease summary index (PDSI) and dif-
ferent dimensions of the health-related quality of life (HRQoL) in Parkinson’s disease patients (n = 157).
Independent Variables Unstandardized Coefficients Standardized Coefficients p-value Collinearity Statistics
Tolerance VIF
Parkinson’s disease summary index (PDSI) (whole model)
Female Sex 5.30 (1.97–8.62) 0.16 0.002* 0.83 1.21
Disease Duration -0.24 (-0.54–0.07) -0.08 0.127 0.78 1.29
Comorbidity Score 1.33 (-0.15–2.81) 0.08 .079 0.97 1.03
Anxiety Score 0.51 (0.15–0.87) 0.17 .006* 0.59 1.70
Depression Score 1.11 (0.63–1.59) 0.32 <0.001* 0.45 2.21
MNA Total Score -0.14 (-0.71–0.43) -0.03 0.634 0.57 1.77
Fatigue Score 0.33 (-0.58–1.24) 0.04 0.48 0.67 1.50
UPDRS Score
Part I-items 1, 2, 4 0.69 (-0.20–1.57) 0.08 0.127 0.71 1.41
Part II- ADL 0.90 (0.60–1.20) 0.43 <0.001* 0.41 2.42
Part III- Motor -0.12 (-0.34–0.10) -0.07 0.269 0.49 2.05
Constant 3.66 (-13.40–20.72) - .672 - -
Dimension I-Mobility (significant predictors)
Female Sex 10.86 (4.12–17.60) 0.19 0.002* 0.83 1.21
Depression Score 1.41 (0.44–2.38) 0.23 0.005* 0.45 2.21
UPDRS Score
Part II- ADL 1.19 (0.59–1.80) 0.33 <0.001* 0.41 2.42
Dimension II-Activity of daily living (ADL) (significant predictors)
Depression Score 1.26 (0.31–2.21) 0.22 0.009* 0.45 2.21
UPDRS Score
Part II- ADL 1.98 (1.39–2.57) 0.57 <0.001* 0.41 2.42
Dimension III-Emotional well-being (significant predictors)
Female Sex 7.18 (1.02–13.34) 0.14 0.023 0.83 1.21
Anxiety Score 1.65 (0.98–2.31) 0.36 <0.001* 0.59 1.70
Depression Score 1.99 (1.11–2.88) 0.37 <0.001* 0.45 2.21
UPDRS Score
Part III- Motor -0.53 (-0.93 – -0.12) -0.20 <0.012* 0.49 2.05
Dimension IV-Stigma (significant predictors)
Anxiety Score 1.15 (0.20–2.10) 0.23 0.018* 0.59 1.70
UPDRS Score
Part II- ADL 0.85 (0.07–1.64) 0.25 0.034* 0.41 2.42
Part III- Motor -0.57 (-1.15–0.01) -0.21 0.055* 0.49 2.05
Dimension V-Social support (significant predictors)
Female Sex 10.44 (3.77–17.12) 0.24 0.002* 0.83 1.21
Depression Score 1.46 (0.50–2.42) 0.31 0.003* 0.45 2.21
UPDRS Score
Part II- ADL 0.72 (0.12–1.31) 0.26 0.019* 0.41 2.42
Dimension VI-Cognitions (significant predictors)
Comorbidity Score 2.63 (0.02–5.24) 0.13 0.048* 0.97 1.03
Anxiety Score 0.62 (-0.01–1.25) 0.16 0.055* 0.59 1.70
UPDRS Score
Part I-items 1, 2, 4 3.85 (2.29–5.40) 0.36 <0.001* 0.71 1.41
Part II- ADL 1.03 (0.50–1.55) 0.38 <0.001* 0.41 2.42
Dimension VII-Communication (significant predictors)
(Continued)
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our findings showed that poorer nutritional status and less psychosocial activity also accompa-
nied with poorer HRQoL in PD patients. The most critical determinants of HRQoL in Iranian
PD patients were motor symptoms affecting their activities of daily life, depression, anxiety,
and female sex, respectively. PD patients with a higher number of comorbidities had in average
a 2.6 poorer score in cognitive dimension. Less severe motor signs, which is usually expected in
the first stages of PD, associated with worse emotional-well being and stigma scores showing
that these domains are mainly affected at the beginning of the disease and coping mechanisms
during the next years could have improved these aspects of HRQoL.
Wu et al also reported that non-motor symptoms, higher motor severity shown by Hoehn
and Yahr score and UPDRS-part III, motor complications, female sex, longer disease duration
and being single or divorced all negatively affect the overall QoL in Chinese PD patients[6].
Their study population[6] was quite similar to ours regarding HRQoL demonstrated by the
average PDSI (21.2 vs. 21.7), which have made these two studies comparable. In line with our
findings, they have also shown that non-motor symptoms are the main drivers of worse
HRQoL in all dimensions. They have used the non-motor symptoms scale of Parkinson's dis-
ease (NMSS) as a general indicator[6], while we have evaluated them with more details and
shown that depression and anxiety are probably the main non-motor determinants of HRQoL
in PD. So far, many other studies have also concluded that non-motor features were the main
determinant factors for HRQoL in parkinsonian patients[1,2,3,4,6,20,21], and some have speci-
fied depression and anxiety as the main non-motor responsible for poor HRQoL[21,22,
23,24,25]. ADL and the level of dependency have been commonly shown to be an important
driver of worse HRQoL in PD[7,26], which is consistent with the independent role of
UPDRS-ADL score in our investigation. Female sex as a risk factor for worse HRQoL in PD
has been shown in some other studies[6], however, still debated with controversial findings in
some other reports[2,5,27]. Although it is believed that the worse QoL in women with a chronic
disease is generally resulted from the higher burden of depression and anxiety, our findings
demonstrated that female sex is an independent risk factor for worsening of HRQoL in PD
even after adjustment for psychiatric symptoms. In another comprehensive assessment on 130
PD patients, Rahman et al also showed that other than depression and anxiety, other non-
motor symptoms such as fatigue, confusion, autonomic disturbance and pain and some motor
problems specifically shuffling, difficulty in turning and dressing, falls and unpredictable fluc-
tuations were the major predictors of worse HRQoL[25].
Table 3. (Continued)
Independent Variables Unstandardized Coefficients Standardized Coefficients p-value Collinearity Statistics
Tolerance VIF
Depression Score 1.33 (0.49–2.17) 0.30 0.002* 0.45 2.21
UPDRS Score
Part II- ADL 0.81 (0.29–1.33) 0.31 0.002* 0.41 2.42
Dimension VIII-Bodily Discomfort (significant predictors)
Female Sex 11.12 (3.97–18.27) 0.23 0.003* 0.83 1.21
UPDRS Score
Part I-items 1, 2, 4 2.28 (0.38–4.18) 0.19 0.019* 0.71 1.41
All models were performed using the independent/covariate variables listed in the first model for Parkinson’s disease summary index (PDSI) as dependent
outcome.
doi:10.1371/journal.pone.0137081.t003
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In addition to regression models, we also applied SEM consisted of global motor, non-
motor and comorbidity components. Statistically, SEMs are stronger models due to the ability
of complex linkage between different components through simultaneous regression equations,
and taking into account interrelationships between predictor variables and observational errors
from measurement of latent variables[28]. Our findings demonstrated that anxiety could
Fig 1. Structural equationmodel for the factors affecting health-related quality of life (HRQoL) in patients with Parkinson’s disease [all
standardized regression weights are statistically significant at p<0.001 except for the effect of comorbidities on HRQoL (p = 0.045), the indication
of motor domain on fluctuations (p = 0.062) and dyskinesia (p = 0.001), and the indication of HRQoL on stigma (p = 0.001)]
doi:10.1371/journal.pone.0137081.g001
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directly strongly affect the emotional well-being domain of HRQoL and seemed to be its main
determinant. Other than the already known indicators, our investigation revealed that nutri-
tional status and fatigue played a key independent role in the non-motor component to affect
HRQoL in PD. Previously, we have shown that PD patients with nutritional insufficiency had
considerably worse HRQoL in all domains except for stigma [9]. Even in a longitudinal study
by Sheard et al, improvement in nutritional status has demonstrated to advance HRQoL in
patients with PD [8]. Most recently, weight loss has been also shown to worsen HRQoL, which
is a common problem and should be noticed by practitioners [29]. These findings highlight the
importance of the association between nutritional status and HRQoL in PD.
Motor and gait complications such as dyskinesia, falls, fluctuations and freezing were all sig-
nificant indicators of the global motor component in its path to affect HRQoL. A considerable
proportion of the overall contribution of motor symptoms in HRQoL mediated through non-
motor component. In addition to this comprehensive general model, we also showed outstand-
ing heterogeneities in the pattern of HRQoL in different PD phenotypes. Interestingly, the
comorbidity component was an important determinant of HRQoL only among those with the
older-onset and non-tremor-dominant PD. Among patients with rapid progression PD, a
chronicity symptom such as fatigue was not a significant indicator of global non-motor section,
while the motor component had a larger direct effect on HRQoL. In contrast, the impact of
motor component on HRQoL was mostly mediated through non-motor symptoms as the
main driver of HRQoL in slow-progression PD. Contribution of global motor component in
HRQoL was remarkably different between the younger-onset and older-onset PD patients such
that the importance of direct effects of motor symptoms on HRQoL was three-fold larger in
younger-onset patients. Among those with the non-tremor dominant phenotype, the global
non-motor component revealed larger contribution in HRQoL, which is in line with the find-
ings from a recent study showing that non-motor symptoms had less involvement in HRQoL
in PD patients with tremor-associated phenotype compared to those who predominantly man-
ifested with axial symptoms [30].
So far, a few structural modelings have been performed to comprehensively elucidate
HRQoL in PD. Visser et al have also constructed an SEM and concluded that psychosocial
well-being had a larger impact on HRQoL than physical functioning among which depression
had the largest contribution followed by axial motor, gastrointestinal, and urinary symptoms
[31]. According to their model other impairments such as pain, psychiatric complications,
motor symptoms, autonomic dysfunction, motor complications, and daytime sleepiness, indi-
rectly affect HRQoL via psychosocial well-being and ADL[31]. Soh et almainly highlighted the
direct contribution of functional disability and falls in HRQoL of PD patients[32]. More
recently, Lee et al have proposed another SEM in which depression and pain were introduced
as the main factors that could directly affect HRQoL in PD[33]. Even though different struc-
tural models have been hypothesized, our findings on the general model are aligned with those
of previous studies. In all SEMs of HRQoL, either functional disabilities or psychiatric well-
being such as depression have been pointed out as the most consistent factors associated with
poorer HRQoL in PD. Nevertheless, there are some differences in the list of variables that have
been used to create these models and none of them have compared the model between different
PD phenotypes.
We should acknowledge our study limitations of which the most important one is its cross-
sectional design. Data on some other important features such as pain, and REM sleep behavior
disorder were not available in our study. Data validity could have been improved by using
more objective methods like polysomnography for sleep disturbances, blood pressure measure-
ment to detect orthostatic hypotension and a full neuropsychological assessment for cognitive
impairments. Still, the comprehensive list of variables and sophisticated statistical method we
Quality of Life in Parkinson's Disease
PLOS ONE | DOI:10.1371/journal.pone.0137081 September 3, 2015 14 / 17
used, have strengthened our investigation. Similar to other previous studies on this topic, we
should also mention that some of the items of the PDQ-39 questionnaire are inherently related
to some non-motor symptoms such as depression, anxiety, sleep disorders and hallucinations,
which might have led to the large contribution of non-motor component on HRQoL
indicators.
In conclusion, our study provides a comprehensive understanding of HRQOL through the
testing of conceptualized structural model, which has demonstrated global motor and non-
motor components and their important indicators to affect HRQoL in addition to the comor-
bidity burden as the main drivers. Clear heterogenic HRQoL patterns were observed in patients
with different phenotypes, which need to be taken into account for future studies. PD patients
with younger-onset, older-onset, slow-progression, rapid-progression, motor-dominant, and
non-motor-dominant phenotype have noticeably different causal pathways and determinants
for HRQoL. These factors should be considered during the assessments and developing person-
alized strategies to improve HRQOL in PD patients with different phenotypes or prominent
feature. Yet, it is necessary to examine the causal order of the determinants of HRQoL using
data from longitudinal studies considering differences in the phenotypic features of PD.
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